Receptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn&#8217;s Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.
